B

BioLineRx Ltd

BLRX

0.69200
USD
-0.098
(-12.41%)
مغلق
حجم التداول
3,134
الربح لكل سهم
0
العائد الربحي
0
P/E
-1
حجم السوق
32,225,116
أصول ذات صلة
ABBV
4.380
(2.36%)
189.700 USD
AMGN
2.78
(0.84%)
335.22 USD
B
BIIB
-2.500
(-1.17%)
210.710 USD
BMY
0.620
(1.30%)
48.180 USD
GILD
0.470
(0.62%)
76.510 USD
GSK
0.865
(2.23%)
39.650 USD
LLY
28.47
(3.54%)
832.74 USD
MRK
0.680
(0.60%)
113.800 USD
PFE
0.115
(0.38%)
30.650 USD
SNY
-0.090
(-0.17%)
51.700 USD
الأخبار المقالات

العنوان: BioLineRx Ltd

القطاع: Healthcare
الصناعة: Biotechnology
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.